Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

ObjectivesDigital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connecti...

Full description

Bibliographic Details
Main Authors:	Andrea Mantovani, Claudia Leopaldi, Cassandra Maria Nighswander, Rossella Di Bidino
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-02-01
Series:	Frontiers in Medical Technology
Subjects:	digital therapeutics in vitro diagnostics reimbursement regulatory access software
Online Access:	https://www.frontiersin.org/articles/10.3389/fmedt.2023.1101476/full

Similar Items

Time to reimbursement and negotiation condition in Italy for drugs approved by the European Medicines Agency during the period 2014-2019
by: Mariangela Prada, et al.
Published: (2020-12-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
by: José Luis Poveda, et al.
Published: (2023-01-01)

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
by: Olga Barszczewska, et al.
Published: (2020-06-01)

Critical Reflections on Reimbursement and Access of Advanced Therapies
by: Steven Simoens, et al.
Published: (2022-05-01)

Stratified Medicine and Reimbursement Issues
by: Hans-Joerg eFugel, et al.
Published: (2012-10-01)

Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis
by: Kyung-Bok Son
Published: (2020-10-01)

Personalized Medicine’s Bottleneck: Diagnostic Test Evidence and Reimbursement
by: Joshua P. Cohen, et al.
Published: (2014-04-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies
by: Entela Xoxi, et al.
Published: (2022-09-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU
by: SungKyung Lee, et al.
Published: (2023-02-01)

A framework for assessing the impact of pharmaceutical reimbursement policies on incentives to innovate
by: Elizabeth Docteur, et al.
Published: (2015-12-01)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
by: Hong Zhu, et al.
Published: (2022-07-01)

Equivalent Modes of Reimbursement in Augmented Contests
by: Chen Cohen, et al.
Published: (2023-03-01)

The Impact of the Clinical Miscoding on Inpatient Reimbursement
by: Roghayeh Ershad Sarabi, et al.
Published: (2020-03-01)

Reimbursement decisions for medical services in Austria: an analysis of influencing factors for the hospital individual services catalogue between 2008 and 2020
by: Gregor Goetz, et al.
Published: (2022-02-01)

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Comparing access to orphan medicinal products in Europe
by: Bernarda Zamora, et al.
Published: (2019-05-01)

Will a Fixed Price Reimbursement Policy for Statins be Cost-Effective for Turkey's Health Care System?
by: Guvenc Kockaya, et al.
Published: (2010-01-01)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
by: Sam Salek, et al.
Published: (2019-03-01)

Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
by: E. Petro, et al.
Published: (2024-12-01)

Reimbursement for Emergency Department Electrocardiography and Radiograph Interpretations: What Is It Worth for the Emergency Physician
by: Wu, Tina, et al.
Published: (2009-08-01)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
by: Maria Kamusheva, et al.
Published: (2018-03-01)

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
by: Sarah Sharman Moser, et al.
Published: (2023-02-01)

Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria
by: Georgi Iskrov, et al.
Published: (2016-02-01)

Trends in Medicare utilization and reimbursement for wound debridement procedures 2012–2017
by: Pranav Puri, et al.
Published: (2022-02-01)

THE PROCEDURE OF REIMBURSEMENT OF THE COSTS INCURRED IN A TRIAL, IN A SUBSEQUENT TRIAL
by: Georgiana COMAN
Published: (2022-06-01)

THEORETICAL AND PRACTICAL ASPECTS REGARDING THE ADJUSTMENT AND REIMBURSEMENT OF VALUE ADDED TAX
by: CIUMAG MARIN, et al.
Published: (2021-10-01)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
by: Paweł Kawalec, et al.
Published: (2017-06-01)

The Impact of Instant Reimbursement of Cross-Regional Medical Services on Hospitalization Costs Incurred by the Floating Population—Evidence from China
by: Xiaodong Zhang, et al.
Published: (2022-06-01)

Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market
by: Mihajlo B Jakovljevic
Published: (2014-03-01)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
by: Michael Kossmeier, et al.
Published: (2021-08-01)

Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape
by: Kostadin Kostadinov, et al.
Published: (2024-02-01)

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations
by: Louise Binder, et al.
Published: (2022-03-01)